Literature DB >> 2651754

Control of serum potassium during fasting in patients with end-stage renal disease.

J D Gifford1, E A Rutsky, K A Kirk, H G McDaniel.   

Abstract

In order to evaluate internal potassium balance in patients with end-stage renal disease (ESRD), epinephrine (0.015 micrograms/kg/min) was infused intravenously into normal control (N = 9) and ESRD subjects (N = 7) after a 26 hour fast. Hyperkalemia developed in ESRD patients after 16 hours of fasting, as compared with control subjects (P = 0.02). The hemodynamic response to epinephrine was similar in the two groups. During epinephrine infusion for one hour, the serum potassium decreased in normal subjects, from 4.3 +/- 0.2 mEq/liter to 3.9 +/- 0.1 mEq/liter, but did not change in ESRD patients (P = 0.005). Serum CO2 declined in ESRD, but not in control subjects, while glucose levels were not different in the two groups. Plasma aldosterone was significantly higher in fasting ESRD patients and failed to decrease during epinephrine infusion as compared to controls. Plasma insulin levels remained low in both groups even though serum glucose levels increased. These results demonstrate that hyperkalemia occurs during fasting in ESRD probably as the result of insulinopenia, and suggest that a diminished response to epinephrine may contribute to hyperkalemia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2651754     DOI: 10.1038/ki.1989.12

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  3 in total

Review 1.  Abnormalities of serum potassium concentration in dialysis-associated hyperglycemia and their correction with insulin: review of published reports.

Authors:  Antonios H Tzamaloukas; Todd S Ing; Moses S Elisaf; Dominic S C Raj; Kostas C Siamopoulos; Mark Rohrscheib; Glen H Murata
Journal:  Int Urol Nephrol       Date:  2010-09-09       Impact factor: 2.370

2.  Effects of Ramadan fasting on moderate to severe chronic kidney disease. A prospective observational study.

Authors:  Amaar A Bakhit; Amr M Kurdi; Junaid J Wadera; Abdulkareem O Alsuwaida
Journal:  Saudi Med J       Date:  2017-01       Impact factor: 1.484

3.  Microfluidic DNA-based potassium nanosensors for improved dialysis treatment.

Authors:  Alexander F Smith; Bin Zhao; Mingxu You; Juan M Jiménez
Journal:  Biomed Eng Online       Date:  2019-06-11       Impact factor: 2.819

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.